{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7","upperLimit":"41","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Will be defined using International IMWG criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients undergo radiation therapy on day 1. Patients also receive pembrolizumab IV over 30 minutes on day 2 or 3. Courses with pembrolizumab repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.\n\nPembrolizumab: Given 200 mg/kg IV.\n\nRadiation Therapy: Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.","id":"OG000","title":"Radiation Therapy, Pembrolizumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 12 months after study start","title":"Number of Participants Who Showed an Overall Response to Treatment Based on Baseline Changes on Positron Emission to Positron Emission Tomography/Computed Tomography","type":"SECONDARY","unitOfMeasure":"participants"}